Rapid Diagnostics for Epidemics are Critical for Surveillance, Outbreak Response, and to Accelerate Elimination Efforts. Mologic have created a technology platform and manufacturing suite that can be applied readily and responsively to outbreak-prone and emerging epidemics. Rapid diagnostics play an essential role for epidemic control and surveillance, particularly in the absence of an effective vaccine or therapy.
Since 2018, Mologic has increased its focus on epidemics and neglected diseases now addressing 14 Targets, supported by the Bill & Melinda Gates Foundation, the Wellcome Trust, the UK government, and the Foundation for Innovative New Diagnostics (FIND).
To ensure access and scale for emergency response, Mologic has committed to ensure all its products are made available at cost to Gavi-eligible countries.
In 2015, the Gates Foundation approached Mologic to create the Centre for Advanced Rapid Diagnostics (CARD). CARD was set up with a $5m grant to redefine lateral flow technology and augment its performance to new heights. BMGF set a target of detecting 1pg/ml of HIV or malaria protein using a $1 visually read diagnostic test that could be deployed at the last mile. This represented a 1,000 improvement on previous technology — but without sophisticated set up, instruments, highly trained staff and electricity. This was achieved in 2018 and a subsequent reinvestment of approx $7m was made to scale the platform.